TALICIA Drug Patent Profile

Which patents cover Talicia, and what generic alternatives are available?

Talicia is a drug marketed by Talicia Holdings and is included in one NDA. There are seven patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in TALICIA is amoxicillin; omeprazole magnesium; rifabutin. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; omeprazole magnesium; rifabutin profile page.

DrugPatentWatch^® Generic Entry Outlook for Talicia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 12, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TALICIA

International Patents:	30
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for TALICIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TALICIA
What excipients (inactive ingredients) are in TALICIA?	TALICIA excipients list
DailyMed Link:	TALICIA at DailyMed

See drug prices for TALICIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TALICIA

Constraining patent/regulatory exclusivity:

10,238,606

NDA:

213004

Dosage:

CAPSULE, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TALICIA

Drug Class	Penicillin-class Antibacterial Proton Pump Inhibitor Rifamycin Antimycobacterial
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

US Patents and Regulatory Information for TALICIA

TALICIA is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,238,606.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,603,806		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	10,238,606		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	11,878,011
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,498,445		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,050,263		Y

International Patents for TALICIA

When does loss-of-exclusivity occur for TALICIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Philippines

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TALICIA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014216373
Brazil	112015019264
Canada	2900763
Chile	2015002253
China	105163743
China	109893516

TALICIA (dexlansoprazole/Amoxicillin) Market Dynamics and Financial Trajectory: Sales Trends, Pricing, Competitive Pressure, and Exclusivity-Driven Outlook

Last updated: July 26, 2026

TALICIA is an FDA-approved fixed-dose combination for the eradication of Helicobacter pylori in adults. Market dynamics are dominated by: (1) payer access and prior authorization, (2) conversion from proton pump inhibitor (PPI) plus generic antibiotic regimens, (3) competitive pressure from other H. pylori regimens with strong formulary placement, and (4) exclusivity and patent overhang that affect near-term generic and follow-on product risk.

What is TALICIA’s commercial profile and how has the market adopted it?

Answer (commercial profile): TALICIA’s uptake is constrained by managed-care controls and the high substitutability of H. pylori therapy to older, lower-cost PPI and antibiotic combinations, including generic regimens.

Where does TALICIA compete in H. pylori treatment?

• Indication: eradication of H. pylori in adults.
• Therapeutic positioning: fixed-dose combination intended to simplify regimen selection and improve adherence versus multi-product therapy.
• Purchase decision drivers:
  • Formulary tiering for the full regimen (not just the PPI component)
  • Step-edit controls (trial of alternative regimens)
  • Prior authorization thresholds tied to guideline adherence
  • Total course cost versus equivalent-duration generic regimens

Payer mechanics that shape sales velocity

• Prior authorization and step therapy: common for specialty and branded antibacterial combinations when lower-cost antibiotic options exist.
• Pharmacy benefit design: if placed on higher cost-sharing tiers, adoption slows even when prescribers are aware of the fixed-dose advantage.
• Contracting: annual or multi-year rebate structures can concentrate access through a subset of national and regional payer formularies.

Adoption reality for fixed-dose H. pylori combinations

Fixed-dose products can win market share when they:

• Reduce treatment complexity (fewer pills per course)
• Are preferred in payer clinical criteria for eradication outcomes
• Are priced competitively after net pricing and rebate assumptions

They lose share when:

• Payer coverage is limited to specific lines of therapy or prior failure criteria
• Equivalent outcomes are achieved with generic PPI plus generic antibiotics at a lower net cost

What is TALICIA’s revenue trajectory and how does pricing/net pricing affect profitability?

Answer (financial trajectory): TALICIA’s financial trajectory depends on net pricing after rebates, payer access depth, and script volumes driven by formulary placement. Branded H. pylori products typically show revenue patterns tightly coupled to managed-care contracting rather than pure market awareness.

Key components of revenue mechanics for TALICIA

• Gross-to-net pricing compression:
  • Brand rebates tied to formulary placement and volume
  • Channel and contracting incentives to pharmacy chains and PBMs
• Use-rate dependence:
  • H. pylori therapy volume is seasonal and guideline-driven, but branded share is payer-dependent
• Course-based sales:
  • H. pylori eradication is typically prescribed as a defined course, so revenue tracks completed prescriptions

Cost structure considerations that influence margin

• Manufacturing complexity: fixed-dose combination packouts add SKU and packaging cost.
• Supply chain robustness: antibiotics component sourcing can drive cost volatility.
• Launch economics: early years often include higher SG&A and market access costs to secure coverage.

What market forces are most likely to move TALICIA sales up or down?

Answer (market forces): Coverage depth and contracting outcomes are the biggest levers. Competitive substitution from generic PPI plus antibiotic regimens can cap branded share unless TALICIA earns strong payer positioning.

Competitive pressure: why generic substitution matters

H. pylori regimens rely on widely available generics:

• PPIs with multiple generics
• Amoxicillin and other antibiotics as generics (depending on regimen structure)

That creates a baseline ceiling for branded fixed-dose products unless:

• Payers treat TALICIA as preferred by clinical criteria
• Net pricing after rebates becomes competitive
• Outcomes data and guideline alignment support a “preferred regimen” status

Other branded/next-in-class risks

Even when direct fixed-dose competitors are limited, clinicians face multiple regimen pathways:

• Alternative branded combinations
• Generic multi-product regimens
• Regimen swaps based on resistance patterns and local practice

When does TALICIA lose exclusivity and how does that affect financial downside?

Answer (exclusivity risk): Generic and follow-on entry risk is driven by patent expiration and regulatory exclusivity status (where applicable). Financial downside usually accelerates after the first meaningful ANDA filing milestones and near-term litigation uncertainty resolution.

What typically controls exclusivity-driven sales impact in fixed-dose H. pylori products

• Patent term expiry for:
  • Composition-of-matter (active ingredient(s))
  • Formulation and fixed-dose ratio claims
  • Method-of-use claims tied to eradication regimens
• Regulatory exclusivity:
  • Any New Chemical Entity (NCE) or other regulatory exclusivity would extend potential generic entry timelines
• Litigation and settlement:
  • If Hatch-Waxman litigation ends with a stipulated stay, generic launch can be delayed despite patent expiry on paper

Financial “cliff” dynamics investors track

• 12- to 24-month lead indicators:
  • ANDA filings
  • Paragraph IV certifications
  • Market rumors around settlement terms
• Post-entry effects:
  • Branded pricing pressure from payer switching to generics
  • Script volume migration to lowest net-cost option

What patents protect TALICIA’s commercial moat and how strong is the estate?

Answer (patent estate framing): The strength and duration of TALICIA’s commercial moat depends on how much of the estate covers fixed-dose composition and use versus only basic PPI/amoxicillin subject matter that is easier to design around.

How patent coverage typically segments in fixed-dose H. pylori combinations

• Composition/fixed-dose claims:
  • Protect the combined composition and ratios
• Formulation claims:
  • Protect dosage form characteristics and release properties
• Method-of-use claims:
  • Protect the eradication regimen protocol

Litigation and licensing impact on net timing

• If TALICIA’s estate includes claims that are difficult to design around, that tends to:
  • Increase likelihood of settlements that delay generic entry
  • Reduce the probability of “at-risk” launch by challengers

How does TALICIA’s FDA and Orange Book status influence generic entry risk?

Answer (Orange Book status): The Orange Book listing scope defines what generics must address with ANDA and certification. The practical risk depends on which patents are listed for the drug product and how they align to claims a challenger can attack.

What the Orange Book listings generally signal

• If multiple patents are listed for the same NDA product, ANDA entrants often face coordinated challenges.
• If only a narrow set of patents is enforceable, entry risk can rise even before full term expiry.

Which companies are most likely to challenge TALICIA and what does Paragraph IV activity imply?

Answer (Paragraph IV signal): Paragraph IV activity is the leading indicator of near-term generic entry risk. The strongest implication comes from:

• Filing timing relative to patent expiry
• Number of challenged patents
• Settlement outcomes that create launch dates

How to interpret challengers strategically

• A challenger targeting only certain patents suggests design-around strategies or a belief that other claims are easier to invalidate.
• A broad challenge increases pressure on the patent owner and increases settlement leverage, but can also trigger longer litigation if the claims are central.

What is the competitive landscape for TALICIA versus alternative H. pylori regimens?

Answer (competitive landscape): TALICIA competes not only with branded regimens but with generic multi-product approaches that can replicate effective therapy at lower cost.

Common substitution pathways payers prefer when TALICIA is not preferred

• Generic PPI plus generic antibiotics used as an equivalent-duration regimen
• Preferred alternative branded products with better rebate positioning
• Regimen selection tied to:
  • Prior antibiotic exposure
  • Regional resistance patterns
  • Formulary restrictions on specific antibiotics

How prescribers choose in practice

• Guideline alignment and local stewardship protocols
• Patient adherence constraints
• Insurance coverage at the point of prescribing
• Prior treatment history

What manufacturing and supply-chain risks could affect TALICIA availability and revenue?

Answer (supply risks): Fixed-dose combination products can face availability shocks from antibiotic component sourcing or packaging bottlenecks. Any disruption translates quickly into lost scripts for a course-based therapy.

Where disruptions hit hardest

• Early pipeline months during ramp
• Timing around seasonal demand for GI therapies
• Any antibiotic component shortages affecting manufacturing allotments

Key takeaways

• TALICIA’s sales velocity is primarily a payer access and contracting story, not a pure clinical preference story.
• Market share is capped by substitution to generic PPI plus antibiotic regimens unless TALICIA holds preferred formulary status.
• Financial downside is tied to exclusivity/patent expiration sequencing and any Paragraph IV activity or settlements that shorten branded launch protection.
• Supply chain stability matters for course-based therapies: availability issues translate quickly into revenue loss.

FAQs

1) What drives TALICIA formulary placement versus generic H. pylori regimens?

Coverage is driven by net pricing after rebates, clinical criteria for preferred regimens, and payer policies that control switching to low-cost multi-product generics.

2) How do PBMs typically evaluate fixed-dose H. pylori combinations like TALICIA?

PBMs evaluate total course cost, outcomes consistency, adherence benefits, and contract terms that determine tier placement and patient cost-sharing.

3) What indicators show TALICIA is nearing generic erosion?

ANDAs with Paragraph IV certifications, litigation milestones, settlement coverage terms, and patent expiry sequencing are the earliest commercial indicators.

4) Does TALICIA’s performance depend more on new-to-therapy patients or switchers?

Switchers dominate near-term share changes because most H. pylori patients have prior medication history and treatment selection occurs via payer-restricted regimen lists.

5) What regimen alternatives most directly compete with TALICIA for eradication?

Generic PPI plus antibiotic multi-product regimens and any preferred branded eradication protocols on payer formularies are the most direct substitutes.

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/